HOUSE-BILL 1100: H.R.1100 - STOPP Act
AI-Powered Summary
HOUSE-BILL 1100 aims to regulate the manufacture, distribution, and sale of tableting and encapsulating machines used in the production of controlled substances. The legislation introduces new registration, reporting, and record-keeping requirements for individuals involved in this industry, thereby impacting their legal operational capabilities. Major themes include public health and safety, as the bill seeks to control the distribution of machines that could facilitate illegal drug production. Key provisions include mandatory registration with the Attorney General, maintenance of detailed transaction records, the establishment of a National Pill Press Registry, and penalties for non-compliance. Implementation will require affected individuals to adapt to these new regulatory burdens, potentially leading to increased scrutiny of their business practices. Constitutional implications arise concerning due process rights, as individuals may face penalties without adequate notice or opportunity for contestation, raising concerns about regulatory overreach. Overall, the bill seeks to balance public safety interests with the rights of individuals in the industry, but it may also impose significant operational challenges and legal considerations for those affected.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The bill's regulatory framework may create significant barriers for individuals involved in the manufacturing and distribution of controlled substances, particularly impacting small businesses and marginalized groups. The potential for criminal liability raises serious due process concerns, as individuals may not have adequate notice of their obligations under the new regulations.
Key Individual Rights Affected
- Due Process (Fifth and Fourteenth Amendments)
- Equal Protection (Fourteenth Amendment)
- Right to Privacy
Constitutional Provisions Most Relevant
- Fifth Amendment - Due Process
- Fourteenth Amendment - Equal Protection
- Fourth Amendment - Right to Privacy
Potential Constitutional Challenges Or Support
Challenges
- Vagueness and overreach in regulatory definitions leading to arbitrary enforcement
- Disproportionate impact on small manufacturers and specific demographic groups, raising equal protection claims
- Criminalization of non-compliance without adequate notice, violating due process rights
Support
- Public health justification for regulating harmful substances
- Legitimate government interest in controlling the manufacturing of drugs to protect society
Summary
While HOUSE-BILL 1100 aims to address public health concerns related to drug manufacturing, it raises significant constitutional issues regarding individual rights. The potential for regulatory overreach, criminal penalties, and unequal treatment under the law could lead to violations of due process and equal protection, particularly affecting vulnerable demographic groups.
Constitutional Analysis
This bill has been analyzed for constitutional compliance using AI-powered analysis of constitutional principles and precedents.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention H.R. 1100 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreePolicy Topics
Timeline
February 6, 2025
Bill Introduced
Current
Referred to Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat